Nektar Therapeutics Says Moventig Gets Positive CHMP Opinion In EU

(RTTNews) - Nektar Therapeutics (NKTR) Friday reported that the investigational Moventig has received a positive opinion from Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA, recommending its approval for the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxatives. This was following a review of comprehensive data from the Kodiac clinical study, which had four trials evaluating the safety and efficacy of Moventig. The opinion will be further reviewed by the European Commission or EC, which has the authority to approve medicines for the European Union. Moventig is an investigational, peripherally-acting mu-opioid receptor antagonist and is part of the exclusive worldwide license agreement between AstraZeneca (AZN) and Nektar Therapeutics.